Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.
We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...
On October 31, Bristol-Myers Squibb (NYSE:BMY) released financial results for the third quarter of 2024, which not only beat ...
1d
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) ...
Fintel on MSN3d
Wolfe Research Initiates Coverage of Bristol-Myers Squibb (BMY) with Peer Perform RecommendationFintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb (NYSE:BMY) with a Peer ...
Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...
On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $59.02 which represents a decrease of $-0.80 or -1.34% from the prior close of $59.82. The stock opened at $59.82 and ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
Morgan Stanley raised the firm’s price target on Bristol Myers (BMY) to $39 from $36 and keeps an Underweight rating on the shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback